Orforglipron
Oral small-molecule GLP-1 receptor agonist taken as a once-daily pill with no food or water timing restrictions. FDA-approved for chronic weight management in April 2026 under the brand Foundayo.
- Half-life
- 1.3 d
- Out of system
- ~6 days
- Route
- Oral
- Level
- Beginner
Daily dosing holds steady levels. After the last dose, roughly 97% has cleared in ~6 days (five half-lives) — the window that matters for washouts, bloodwork and surgery.
What Orforglipron is used for
- Delivers injectable-class GLP-1 weight loss and blood-sugar control in a convenient daily pill
- No food or water timing restrictions, unlike other oral GLP-1 options
- FDA-approved for chronic weight management, so quality and dosing are standardized
How it's typically used
Trial and label range: titrated daily oral doses commonly from 6 mg up to 36 mg for weight management, as reported in the literature.
What to watch for
- Common GI side effects include nausea, vomiting, diarrhea and constipation, especially during titration
- Shares GLP-1 class warnings including gallbladder issues and a boxed thyroid C-cell tumor concern
- Prescription medication (FDA-approved April 2026, brand Foundayo); use only under medical supervision
About GLP-1 & weight loss
- What they are
- Incretin analogues — GLP-1 and dual/triple agonists. They slow stomach emptying and act on appetite centres in the brain, so you eat less without white-knuckling it.
- How they're run
- One subcutaneous shot a week for most, on the same day each week. Doses climb in steps every four weeks; that slow titration is what keeps side effects tolerable.
- What to watch
- Nausea, constipation, and reflux are near-universal in the first month. Muscle is lost alongside fat unless you keep protein high and keep lifting. Tell any surgeon or anaesthetist you are on one.
Full guide
Orforglipron: A Tracking Guide for an Oral Small-Molecule GLP-1
A measured, harm-reduction look at orforglipron, a non-peptide GLP-1 pill approved for obesity, and what actually matters to track.
Other glp-1 & weight loss
Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.